Mutational heterogeneity in cancer and the search for new cancer-associated genes
Open accessThe DOI matches its Crossref record; 31 of the 31 references it cites were found in a registry or an index.
Abstract
Major international projects are underway that are aimed at creating a comprehensive catalogue of all the genes responsible for the initiation and progression of cancer. These studies involve the sequencing of matched tumour-normal samples followed by mathematical analysis to identify those genes in which mutations occur more frequently than expected by random chance. Here we describe a fundamental problem with cancer genome studies: as the sample size increases, the list of putatively significant genes produced by current analytical methods burgeons into the hundreds. The list includes many implausible genes (such as those encoding olfactory receptors and the muscle protein titin), suggesting extensive false-positive findings that overshadow true driver events. We show that this problem stems largely from mutational heterogeneity and provide a novel analytical methodology, MutSigCV, for resolving the problem. We apply MutSigCV to exome sequences from 3,083 tumour-normal pairs and discover extraordinary variation in mutation frequency and spectrum within cancer types, which sheds light on mutational processes and disease aetiology, and in mutation frequency across the genome, which is strongly correlated with DNA replication timing and also with transcriptional activity. By incorporating mutational heterogeneity into the analyses, MutSigCV is able to eliminate most of the apparent artefactual findings and enable the identification of genes truly associated with cancer.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“The reproducibility of scientific findings has been called into question.”
From Evaluating replicability of laboratory experiments in economics (2016) · cites this paper as [8]
Experimental — accuracy not yet measuredThe cited source says what the claim attributes to it.
In the citing paper
“Melanoma has one of the highest rates of mutation of any cancer16.”
From Mechanisms and prevention of UV‐induced melanoma (2018) · cites this paper as [16]
The check wasn’t confident either way, so it gives no verdict — never disputed.
In the citing paper
“Cancer cells are genetically unstable, which contributes to their uncontrolled proliferation and the expression of antigens that can be recognized by the immune system.”
From Anti-PD-1 and Anti-CTLA-4 Therapies in Cancer: Mechanisms of Action, Efficacy, and Limitations (2018) · cites this paper as [1]
Experimental — accuracy not yet measured
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Comprehensive molecular characterization of human colon and rectal cancer
The Cancer Genome Atlas Network (2012) · Nature · doi:10.1038/nature11252 · Cited by 8,499
Integrated genomic analyses of ovarian carcinoma
Perou, C. M. (2019) · Carolina Digital Repository (University of North Carolina at Chapel Hill) · doi:10.17615/hvp3-wg08 · Cited by 7,925
Comprehensive genomic characterization defines human glioblastoma genes and core pathways
The Cancer Genome Atlas Research Network (2008) · Nature · doi:10.1038/nature07385 · Cited by 7,735
Self-citationAn Integrated Genomic Analysis of Human Glioblastoma Multiforme
Parsons, D. W., Jones, S., Zhang, X., Lin, J. C.-H., Leary, R. J., Angenendt, P., Mankoo, P., Carter, H., Siu, I.-M., Gallia, G. L., et al. (2008) · Science · doi:10.1126/science.1164382 · Cited by 5,857 · cited 2×
“…(GBM) 2 and lung adenocarcinoma 1,4 ; CSMD3 in ovarian cancer 2 ; PCLO in diffuse large B-cell lymphoma (DLBCL) 9 ; MUC16 in lung squamous carcinoma 11 , breast cancer 12 and DLBCL 8 ; MUC4 in melanoma 13 ; olfactory receptor OR2L13 in GBM 14 ; and TTN in breast cancer 12 and other tumor types 15 .”
Sensitive detection of somatic point mutations in impure and heterogeneous cancer samples
Cibulskis, K., Lawrence, M. S., Carter, S. L., Sivachenko, A., Jaffe, D., Sougnez, C., Gabriel, S., Meyerson, M., Lander, E. S., & Getz, G. (2013) · Nature Biotechnology · doi:10.1038/nbt.2514 · Cited by 4,981
Self-citationComprehensive genomic characterization of squamous cell lung cancers
The Cancer Genome Atlas Research Network (2012) · Nature · doi:10.1038/nature11404 · Cited by 3,994
Self-citationPatterns of somatic mutation in human cancer genomes
Greenman, C., Stephens, P., Smith, R., Dalgliesh, G. L., Hunter, C., Bignell, G., Davies, H., Teague, J., Butler, A., Stevens, C., et al. (2007) · Nature · doi:10.1038/nature05610 · Cited by 3,080
Somatic mutations affect key pathways in lung adenocarcinoma
Ding, L., Getz, G., Wheeler, D. A., Mardis, E. R., McLellan, M. D., Cibulskis, K., Sougnez, C., Greulich, H., Muzny, D. M., Morgan, M. B., et al. (2008) · Nature · doi:10.1038/nature07423 · Cited by 2,681 · cited 1×
“…genes have already cropped up in recently published cancer genome studies, for example: LRP1B in glioblastoma (GBM) 2 and lung adenocarcinoma 1,4 ; CSMD3 in ovarian cancer 2 ; PCLO in diffuse large B-cell lymphoma (DLBCL) 9 ; MUC16 in lung squamous carcinoma 11 , breast cancer 12 and DLBCL 8…”
Self-citationThe Mutational Landscape of Head and Neck Squamous Cell Carcinoma
Stransky, N., Egloff, A. M., Tward, A. D., Kostic, A. D., Cibulskis, K., Sivachenko, A., Kryukov, G. V., Lawrence, M. S., Sougnez, C., McKenna, A., et al. (2011) · Science · doi:10.1126/science.1208130 · Cited by 2,504 · cited 2×
“Recent studies have also implicated HPV in head-and-neck cancers 5 .”
InfluentialSelf-citationMutational Processes Molding the Genomes of 21 Breast Cancers
Nik-Zainal, S., Alexandrov, L. B., Wedge, D. C., Van Loo, P., Greenman, C. D., Raine, K., Jones, D., Hinton, J., Marshall, J., Stebbings, L. A., et al. (2012) · Cell · doi:10.1016/j.cell.2012.04.024 · Cited by 1,909 · cited 3×
“Recent work 19,20 has shown that the TpC mutations tend to occur in proximity to one another, consistent with the activity of APOBEC enzymes in damaged long single-strand DNA regions.”
Influential
Cited by
Items 201–300 of 1,039
Cancer-Specific Retargeting of BAF Complexes by a Prion-like Domain
Boulay, G., Sandoval, G. J., Riggi, N., Iyer, S., Buisson, R., Naigles, B., Awad, M. E., Rengarajan, S., Volorio, A., McBride, M. J., et al. (2017) · Cell · doi:10.1016/j.cell.2017.07.036 · Cited by 470
Self-citationComprehensive identification of mutational cancer driver genes across 12 tumor types
Tamborero, D., Gonzalez-Perez, A., Perez-Llamas, C., Deu-Pons, J., Kandoth, C., Reimand, J., Lawrence, M. S., Getz, G., Bader, G. D., Ding, L., et al. (2013) · Scientific Reports · doi:10.1038/srep02650 · Cited by 484
Self-citationSolomon, B., Young, R. J., & Rischin, D. (2018) · Seminars in Cancer Biology · doi:10.1016/j.semcancer.2018.01.008 · Cited by 467
Comprehensive molecular characterization of mitochondrial genomes in human cancers
Yuan, Y., Ju, Y. S., Kim, Y., Li, J., Wang, Y., Yoon, C. J., Yang, Y., Martincorena, I., Creighton, C. J., Weinstein, J. N., et al. (2020) · Nature Genetics · doi:10.1038/s41588-019-0557-x · Cited by 465
Genome-wide analysis of noncoding regulatory mutations in cancer
Weinhold, N., Jacobsen, A., Schultz, N., Sander, C., & Lee, W. (2014) · Nature Genetics · doi:10.1038/ng.3101 · Cited by 484
Aberrant RNA splicing in cancer; expression changes and driver mutations of splicing factor genes
Sveen, A., Kilpinen, S., Ruusulehto, A., Lothe, R. A., & Skotheim, R. I. (2016) · Oncogene · doi:10.1038/onc.2015.318 · Cited by 470
Perry, J. A., Kiezun, A., Tonzi, P., Van Allen, E. M., Carter, S. L., Baca, S. C., Cowley, G. S., Bhatt, A. S., Rheinbay, E., Pedamallu, C. S., et al. (2014) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1419260111 · Cited by 481
Self-citationIdentification of novel mutational drivers reveals oncogene dependencies in multiple myeloma
Walker, B. A., Mavrommatis, K., Wardell, C. P., Ashby, T. C., Bauer, M., Davies, F. E., Rosenthal, A., Wang, H., Qu, P., Hoering, A., et al. (2018) · Blood · doi:10.1182/blood-2018-03-840132 · Cited by 475
Self-citationA genome-based model for adjusting radiotherapy dose (GARD): a retrospective, cohort-based study
Scott, J. G., Berglund, A., Schell, M. J., Mihaylov, I., Fulp, W. J., Yue, B., Welsh, E., Caudell, J. J., Ahmed, K., Strom, T. S., et al. (2017) · The Lancet Oncology · doi:10.1016/s1470-2045(16)30648-9 · Cited by 474
A clinically applicable integrative molecular classification of meningiomas
Nassiri, F., Liu, J., Patil, V., Mamatjan, Y., Wang, J. Z., Hugh-White, R., Macklin, A. M., Khan, S., Singh, O., Karimi, S., et al. (2021) · Nature · doi:10.1038/s41586-021-03850-3 · Cited by 449
Next-Generation Sequencing in Oncology: Genetic Diagnosis, Risk Prediction and Cancer Classification
Kamps, R., Brandão, R., Bosch, B., Paulussen, A., Xanthoulea, S., Blok, M., & Romano, A. (2017) · International Journal of Molecular Sciences · doi:10.3390/ijms18020308 · Cited by 453
Riggi, N., Knoechel, B., Gillespie, S. M., Rheinbay, E., Boulay, G., Suvà, M. L., Rossetti, N. E., Boonseng, W. E., Oksuz, O., Cook, E. B., et al. (2014) · Cancer Cell · doi:10.1016/j.ccell.2014.10.004 · Cited by 445
“The importance of the translocation is further supported by the fact that it occurs in the setting of one of the lowest mutation rates among all cancer types (Lawrence et al., 2013).”
BackgroundLong noncoding RNAs in cancer: mechanisms of action and technological advancements
Bartonicek, N., Maag, J. L. V., & Dinger, M. E. (2016) · Molecular Cancer · doi:10.1186/s12943-016-0530-6 · Cited by 459
Targeting cancer with kinase inhibitors
Gross, S., Rahal, R., Stransky, N., Lengauer, C., & Hoeflich, K. P. (2015) · Journal of Clinical Investigation · doi:10.1172/jci76094 · Cited by 444
Self-citationRole of non-coding sequence variants in cancer
Khurana, E., Fu, Y., Chakravarty, D., Demichelis, F., Rubin, M. A., & Gerstein, M. (2016) · Nature Reviews Genetics · doi:10.1038/nrg.2015.17 · Cited by 468
Rodriguez-Martin, B., Alvarez, E. G., Baez-Ortega, A., Zamora, J., Supek, F., Demeulemeester, J., Santamarina, M., Ju, Y. S., Temes, J., Garcia-Souto, D., et al. (2020) · Nature Genetics · doi:10.1038/s41588-019-0562-0 · Cited by 451
Self-citationInstitutional implementation of clinical tumor profiling on an unselected cancer population
Sholl, L. M., Do, K., Shivdasani, P., Cerami, E., Dubuc, A. M., Kuo, F. C., Garcia, E. P., Jia, Y., Davineni, P., Abo, R. P., et al. (2016) · JCI Insight · doi:10.1172/jci.insight.87062 · Cited by 450
Self-citationThe landscape and therapeutic relevance of cancer-associated transcript fusions
Yoshihara, K., Wang, Q., Torres-Garcia, W., Zheng, S., Vegesna, R., Kim, H., & Verhaak, R. G. W. (2015) · Oncogene · doi:10.1038/onc.2014.406 · Cited by 450
CTCF/cohesin-binding sites are frequently mutated in cancer
Katainen, R., Dave, K., Pitkänen, E., Palin, K., Kivioja, T., Välimäki, N., Gylfe, A. E., Ristolainen, H., Hänninen, U. A., Cajuso, T., et al. (2015) · Nature Genetics · doi:10.1038/ng.3335 · Cited by 447
Li, M., Zhang, Z., Li, X., Ye, J., Wu, X., Tan, Z., Liu, C., Shen, B., Wang, X.-A., Wu, W., et al. (2014) · Nature Genetics · doi:10.1038/ng.3030 · Cited by 443
'Final common pathway' of human cancer immunotherapy: targeting random somatic mutations
Tran, E., Robbins, P. F., & Rosenberg, S. A. (2017) · Nature Immunology · doi:10.1038/ni.3682 · Cited by 443
Seiler, M., Peng, S., Agrawal, A. A., Palacino, J., Teng, T., Zhu, P., Smith, P. G., Caesar-Johnson, S. J., Demchok, J. A., Felau, I., et al. (2018) · Cell Reports · doi:10.1016/j.celrep.2018.01.088 · Cited by 444
Self-citationIntegrated Molecular Characterization of Uterine Carcinosarcoma
Cherniack, A. D., Shen, H., Walter, V., Stewart, C., Murray, B. A., Bowlby, R., Hu, X., Ling, S., Soslow, R. A., Broaddus, R. R., et al. (2017) · Cancer Cell · doi:10.1016/j.ccell.2017.02.010 · Cited by 434
Self-citationGenomic landscape of cutaneous T cell lymphoma
Choi, J., Goh, G., Walradt, T., Hong, B. S., Bunick, C. G., Chen, K., Bjornson, R. D., Maman, Y., Wang, T., Tordoff, J., et al. (2015) · Nature Genetics · doi:10.1038/ng.3356 · Cited by 428
Multiplex assessment of protein variant abundance by massively parallel sequencing
Matreyek, K. A., Starita, L. M., Stephany, J. J., Martin, B., Chiasson, M. A., Gray, V. E., Kircher, M., Khechaduri, A., Dines, J. N., Hause, R. J., et al. (2018) · Nature Genetics · doi:10.1038/s41588-018-0122-z · Cited by 436
Mutational landscape of intrahepatic cholangiocarcinoma
Zou, S., Li, J., Zhou, H., Frech, C., Jiang, X., Chu, J. S. C., Zhao, X., Li, Y., Li, Q., Wang, H., et al. (2014) · Nature Communications · doi:10.1038/ncomms6696 · Cited by 434
the ICGC Prostate Group, Cooper, C. S., Eeles, R., Wedge, D. C., Van Loo, P., Gundem, G., Alexandrov, L. B., Kremeyer, B., Butler, A., Lynch, A. G., et al. (2015) · Nature Genetics · doi:10.1038/ng.3221 · Cited by 434
Precise estimates of mutation rate and spectrum in yeast
Zhu, Y. O., Siegal, M. L., Hall, D. W., & Petrov, D. A. (2014) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1323011111 · Cited by 420
Ahn, S., Jang, S. J., Shim, J. H., Kim, D., Hong, S., Sung, C. O., Baek, D., Haq, F., Ansari, A. A., Lee, S. Y., et al. (2014) · Hepatology · doi:10.1002/hep.27198 · Cited by 424
Self-citationEccles, S. A., Aboagye, E. O., Ali, S., Anderson, A. S., Armes, J., Berditchevski, F., Blaydes, J. P., Brennan, K., Brown, N. J., Bryant, H. E., et al. (2013) · Breast Cancer Research · doi:10.1186/bcr3493 · Cited by 421
TP53 Mutations in Human Cancer: Database Reassessment and Prospects for the Next Decade
Leroy, B., Anderson, M., & Soussi, T. (2014) · Human Mutation · doi:10.1002/humu.22552 · Cited by 408
Cheng, L., Lopez-Beltran, A., Massari, F., MacLennan, G. T., & Montironi, R. (2018) · Modern Pathology · doi:10.1038/modpathol.2017.104 · Cited by 407
Exome sequencing identifies recurrent mutations in NF1 and RASopathy genes in sun-exposed melanomas
Krauthammer, M., Kong, Y., Bacchiocchi, A., Evans, P., Pornputtapong, N., Wu, C., McCusker, J. P., Ma, S., Cheng, E., Straub, R., et al. (2015) · Nature Genetics · doi:10.1038/ng.3361 · Cited by 402
Self-citationSuda, K., Nakaoka, H., Yoshihara, K., Ishiguro, T., Tamura, R., Mori, Y., Yamawaki, K., Adachi, S., Takahashi, T., Kase, H., et al. (2018) · Cell Reports · doi:10.1016/j.celrep.2018.07.037 · Cited by 414
Chan, K., Roberts, S. A., Klimczak, L. J., Sterling, J. F., Saini, N., Malc, E. P., Kim, J., Kwiatkowski, D. J., Fargo, D. C., Mieczkowski, P. A., et al. (2015) · Nature Genetics · doi:10.1038/ng.3378 · Cited by 414
Self-citationIbrutinib Unmasks Critical Role of Bruton Tyrosine Kinase in Primary CNS Lymphoma
Grommes, C., Pastore, A., Palaskas, N., Tang, S. S., Campos, C., Schartz, D., Codega, P., Nichol, D., Clark, O., Hsieh, W.-Y., et al. (2017) · Cancer Discovery · doi:10.1158/2159-8290.cd-17-0613 · Cited by 409
The genomic landscape of pediatric acute lymphoblastic leukemia
Brady, S. W., Roberts, K. G., Gu, Z., Shi, L., Pounds, S., Pei, D., Cheng, C., Dai, Y., Devidas, M., Qu, C., et al. (2022) · Nature Genetics · doi:10.1038/s41588-022-01159-z · Cited by 391
Kim, H., Zheng, S., Amini, S. S., Virk, S. M., Mikkelsen, T., Brat, D. J., Grimsby, J., Sougnez, C., Muller, F., Hu, J., et al. (2015) · Genome Research · doi:10.1101/gr.180612.114 · Cited by 411
Self-citationSomatic ERCC2 mutations are associated with a distinct genomic signature in urothelial tumors
Kim, J., Mouw, K. W., Polak, P., Braunstein, L. Z., Kamburov, A., Tiao, G., Kwiatkowski, D. J., Rosenberg, J. E., Van Allen, E. M., D'Andrea, A. D., et al. (2016) · Nature Genetics · doi:10.1038/ng.3557 · Cited by 413
Self-citationGenomic basis for RNA alterations in cancer
PCAWG Transcriptome Core Group, Calabrese, C., Davidson, N. R., Demircioğlu, D., Fonseca, N. A., He, Y., Kahles, A., Lehmann, K.-V., Liu, F., Shiraishi, Y., et al. (2020) · Nature · doi:10.1038/s41586-020-1970-0 · Cited by 393
“Although, as expected, skin melanoma significantly exceeds other cancers in the number of non-synonymous SNVs 48 (Wilcoxon rank-sum test, P 0.012), lymphatic cancers have low numbers of SNVs (Wilcoxon rank-sum test, P = 5.3 × 10 −15 ), but high incidences of alternative splicing outliers…”
BackgroundInfluentialSelf-citationIntegrative Clinical Sequencing in the Management of Refractory or Relapsed Cancer in Youth
Mody, R. J., Wu, Y.-M., Lonigro, R. J., Cao, X., Roychowdhury, S., Vats, P., Frank, K. M., Prensner, J. R., Asangani, I., Palanisamy, N., et al. (2015) · JAMA · doi:10.1001/jama.2015.10080 · Cited by 411
Anticancer drug resistance: An update and perspective
Nussinov, R., Tsai, C.-J., & Jang, H. (2021) · Drug Resistance Updates · doi:10.1016/j.drup.2021.100796 · Cited by 386
Dong, L., Lu, D., Chen, R., Lin, Y., Zhu, H., Zhang, Z., Cai, S., Cui, P., Song, G., Rao, D., et al. (2022) · Cancer Cell · doi:10.1016/j.ccell.2021.12.006 · Cited by 390
Predictive biomarkers in PD-1/PD-L1 checkpoint blockade immunotherapy
Meng, X., Huang, Z., Teng, F., Xing, L., & Yu, J. (2015) · Cancer Treatment Reviews · doi:10.1016/j.ctrv.2015.11.001 · Cited by 401
Sharma, P., Pachynski, R. K., Narayan, V., Fléchon, A., Gravis, G., Galsky, M. D., Mahammedi, H., Patnaik, A., Subudhi, S. K., Ciprotti, M., et al. (2020) · Cancer Cell · doi:10.1016/j.ccell.2020.08.007 · Cited by 406
Genomic alterations in lung adenocarcinoma
Devarakonda, S., Morgensztern, D., & Govindan, R. (2015) · The Lancet Oncology · doi:10.1016/s1470-2045(15)00077-7 · Cited by 404
Hypermutation in human cancer genomes: footprints and mechanisms
Roberts, S. A., & Gordenin, D. A. (2014) · Nature Reviews Cancer · doi:10.1038/nrc3816 · Cited by 405
Self-citationthe Oesophageal Cancer Clinical and Molecular Stratification (OCCAMS) Consortium, Secrier, M., Li, X., de Silva, N., Eldridge, M. D., Contino, G., Bornschein, J., MacRae, S., Grehan, N., O'Donovan, M., et al. (2016) · Nature Genetics · doi:10.1038/ng.3659 · Cited by 405
Landau, D. A., Clement, K., Ziller, M. J., Boyle, P., Fan, J., Gu, H., Stevenson, K., Sougnez, C., Wang, L., Li, S., et al. (2014) · Cancer Cell · doi:10.1016/j.ccell.2014.10.012 · Cited by 394
Self-citationExosomal PD-L1 promotes tumor growth through immune escape in non-small cell lung cancer
Kim, D. H., Kim, H., Choi, Y. J., Kim, S. Y., Lee, J.-E., Sung, K. J., Sung, Y. H., Pack, C.-G., Jung, M.-K., Han, B., et al. (2019) · Experimental & Molecular Medicine · doi:10.1038/s12276-019-0295-2 · Cited by 374
Mutational Profile of Metastatic Breast Cancers: A Retrospective Analysis
Lefebvre, C., Bachelot, T., Filleron, T., Pedrero, M., Campone, M., Soria, J.-C., Massard, C., Lévy, C., Arnedos, M., Lacroix-Triki, M., et al. (2016) · PLOS Medicine · doi:10.1371/journal.pmed.1002201 · Cited by 394
“To identify significantly mutated genes, we used the Mutation Significance (MutSig) [17], Mutational Mutational Profile of Metastatic Breast Cancers”
MethodMedicinal Plants of the Family Lamiaceae in Pain Therapy: A Review
Uritu, C. M., Mihai, C. T., Stanciu, G.-D., Dodi, G., Alexa-Stratulat, T., Luca, A., Leon-Constantin, M.-M., Stefanescu, R., Bild, V., Melnic, S., et al. (2018) · Pain Research and Management · doi:10.1155/2018/7801543 · Cited by 367
“M. officinalis exhibit antiviral effects against Newcastle disease virus, Semliki forest virus, inbuenza virus, myxoviruses, vaccinia [240 simplex virus types 1 and 2 [241], HIV-1 [242].”
BackgroundGoh, G., Walradt, T., Markarov, V., Blom, A., Riaz, N., Doumani, R., Stafstrom, K., Moshiri, A., Yelistratova, L., Levinsohn, J., et al. (2016) · Oncotarget · doi:10.18632/oncotarget.6494 · Cited by 387
Mutational Strand Asymmetries in Cancer Genomes Reveal Mechanisms of DNA Damage and Repair
Haradhvala, N. J., Polak, P., Stojanov, P., Covington, K. R., Shinbrot, E., Hess, J. M., Rheinbay, E., Kim, J., Maruvka, Y. E., Braunstein, L. Z., et al. (2016) · Cell · doi:10.1016/j.cell.2015.12.050 · Cited by 411
“The APOBEC signature consists of C/G and C/T mutations in the context TCW (W = A or T) and is thought to reflect the activity of APOBEC-family cytidine deaminase enzymes (Alexandrov et al., 2013; Lawrence et al., 2013; Roberts et al., 2013).”
InfluentialSelf-citationStanding the test of time: targeting thymidylate biosynthesis in cancer therapy
Wilson, P. M., Danenberg, P. V., Johnston, P. G., Lenz, H.-J., & Ladner, R. D. (2014) · Nature Reviews Clinical Oncology · doi:10.1038/nrclinonc.2014.51 · Cited by 388
The Integrated Genomic Landscape of Thymic Epithelial Tumors
Radovich, M., Pickering, C. R., Felau, I., Ha, G., Zhang, H., Jo, H., Hoadley, K. A., Anur, P., Zhang, J., McLellan, M., et al. (2018) · Cancer Cell · doi:10.1016/j.ccell.2018.01.003 · Cited by 381
“MutSig2CV (Lawrence et al., 2013) identified four significantly mutated genes with q 0.1 (Figure 1).”
BackgroundInfluentialSelf-citationZill, O. A., Banks, K. C., Fairclough, S. R., Mortimer, S. A., Vowles, J. V., Mokhtari, R., Gandara, D. R., Mack, P. C., Odegaard, J. I., Nagy, R. J., et al. (2018) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-17-3837 · Cited by 391
Prospects of immune checkpoint modulators in the treatment of glioblastoma
Preusser, M., Lim, M., Hafler, D. A., Reardon, D. A., & Sampson, J. H. (2015) · Nature Reviews Neurology · doi:10.1038/nrneurol.2015.139 · Cited by 388
The role of enhancers in cancer
Sur, I., & Taipale, J. (2016) · Nature Reviews Cancer · doi:10.1038/nrc.2016.62 · Cited by 389
Heterogeneity of epidermal growth factor receptor signalling networks in glioblastoma
Furnari, F. B., Cloughesy, T. F., Cavenee, W. K., & Mischel, P. S. (2015) · Nature Reviews Cancer · doi:10.1038/nrc3918 · Cited by 381
Whole genome sequencing analysis for cancer genomics and precision medicine
Nakagawa, H., & Fujita, M. (2018) · Cancer Science · doi:10.1111/cas.13505 · Cited by 375
Current Landscape of Immunotherapy in Breast Cancer: A Review
Adams, S., Gatti-Mays, M. E., Kalinsky, K., Korde, L. A., Sharon, E., Amiri-Kordestani, L., Bear, H., McArthur, H. L., Frank, E., Perlmutter, J., et al. (2019) · JAMA Oncology · doi:10.1001/jamaoncol.2018.7147 · Cited by 384
Improved Survival with T Cell Clonotype Stability After Anti–CTLA-4 Treatment in Cancer Patients
Cha, E., Klinger, M., Hou, Y., Cummings, C., Ribas, A., Faham, M., & Fong, L. (2014) · Science Translational Medicine · doi:10.1126/scitranslmed.3008211 · Cited by 383
Genomic Analysis of Smoothened Inhibitor Resistance in Basal Cell Carcinoma
Sharpe, H. J., Pau, G., Dijkgraaf, G. J., Basset-Seguin, N., Modrusan, Z., Januario, T., Tsui, V., Durham, A. B., Dlugosz, A. A., Haverty, P. M., et al. (2015) · Cancer Cell · doi:10.1016/j.ccell.2015.02.001 · Cited by 382
Driver and Passenger Mutations in Cancer
Pon, J. R., & Marra, M. A. (2015) · Annual Review of Pathology: Mechanisms of Disease · doi:10.1146/annurev-pathol-012414-040312 · Cited by 355
Evaluating the evaluation of cancer driver genes
Tokheim, C. J., Papadopoulos, N., Kinzler, K. W., Vogelstein, B., & Karchin, R. (2016) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1616440113 · Cited by 384
Ng, A. W. T., Poon, S. L., Huang, M. N., Lim, J. Q., Boot, A., Yu, W., Suzuki, Y., Thangaraju, S., Ng, C. C. Y., Tan, P., et al. (2017) · Science Translational Medicine · doi:10.1126/scitranslmed.aan6446 · Cited by 381
Genomic characterization of biliary tract cancers identifies driver genes and predisposing mutations
Wardell, C. P., Fujita, M., Yamada, T., Simbolo, M., Fassan, M., Karlic, R., Polak, P., Kim, J., Hatanaka, Y., Maejima, K., et al. (2018) · Journal of Hepatology · doi:10.1016/j.jhep.2018.01.009 · Cited by 373
Self-citationNOTCH1 Mutations Occur Early during Cutaneous Squamous Cell Carcinogenesis
South, A. P., Purdie, K. J., Watt, S. A., Haldenby, S., den Breems, N. Y., Dimon, M., Arron, S. T., Kluk, M. J., Aster, J. C., McHugh, A., et al. (2014) · Journal of Investigative Dermatology · doi:10.1038/jid.2014.154 · Cited by 357
Mechanisms of Cancer Resistance to Immunotherapy
Bai, R., Chen, N., Li, L., Du, N., Bai, L., Lv, Z., Tian, H., & Cui, J. (2020) · Frontiers in Oncology · doi:10.3389/fonc.2020.01290 · Cited by 353
SMARCB1-mediated SWI/SNF complex function is essential for enhancer regulation
Wang, X., Lee, R. S., Alver, B. H., Haswell, J. R., Wang, S., Mieczkowski, J., Drier, Y., Gillespie, S. M., Archer, T. C., Wu, J. N., et al. (2017) · Nature Genetics · doi:10.1038/ng.3746 · Cited by 370
Self-citationChen, K., Chen, Z., Wu, D., Zhang, L., Lin, X., Su, J., Rodriguez, B., Xi, Y., Xia, Z., Chen, X., et al. (2015) · Nature Genetics · doi:10.1038/ng.3385 · Cited by 373
Somatic mutation of CDKN1B in small intestine neuroendocrine tumors
Francis, J. M., Kiezun, A., Ramos, A. H., Serra, S., Pedamallu, C. S., Qian, Z. R., Banck, M. S., Kanwar, R., Kulkarni, A. A., Karpathakis, A., et al. (2013) · Nature Genetics · doi:10.1038/ng.2821 · Cited by 369
Self-citationMechanisms and prevention of UV‐induced melanoma
Sample, A., & He, Y. (2018) · Photodermatology, Photoimmunology & Photomedicine · doi:10.1111/phpp.12329 · Cited by 372
The genomic landscape of nasopharyngeal carcinoma
Lin, D.-C., Meng, X., Hazawa, M., Nagata, Y., Varela, A. M., Xu, L., Sato, Y., Liu, L.-Z., Ding, L.-W., Sharma, A., et al. (2014) · Nature Genetics · doi:10.1038/ng.3006 · Cited by 366
Computational pan-genomics: status, promises and challenges
(2016) · Briefings in Bioinformatics · doi:10.1093/bib/bbw089 · Cited by 287
Real-time Genomic Characterization of Advanced Pancreatic Cancer to Enable Precision Medicine
Aguirre, A. J., Nowak, J. A., Camarda, N. D., Moffitt, R. A., Ghazani, A. A., Hazar-Rethinam, M., Raghavan, S., Kim, J., Brais, L. K., Ragon, D., et al. (2018) · Cancer Discovery · doi:10.1158/2159-8290.cd-18-0275 · Cited by 367
Self-citationBillon, P., Bryant, E. E., Joseph, S. A., Nambiar, T. S., Hayward, S. B., Rothstein, R., & Ciccia, A. (2017) · Molecular Cell · doi:10.1016/j.molcel.2017.08.008 · Cited by 363
“…suppressor genes (TSGs) listed in the Cancer Gene Census (e.g., TP53, PTEN, VHL, APC, ATM, and SETD2) and an additional 13 putative TSGs identified by previously published methods, such as TUSON, MutSigCV, and 20/20+ (Davoli et al., 2013; Lawrence et al., 2013; Tokheim et al., 2016) (Figure S5B).”
MethodIndia Project Team of the International Cancer Genome Consortium, Maitra, A., Biswas, N. K., Amin, K., Kowtal, P., Kumar, S., Das, S., Sarin, R., Majumder, P. P., Bagchi, I., et al. (2013) · Nature Communications · doi:10.1038/ncomms3873 · Cited by 355
Machine learning for multi-omics data integration in cancer
Cai, Z., Poulos, R. C., Liu, J., & Zhong, Q. (2022) · iScience · doi:10.1016/j.isci.2022.103798 · Cited by 327
Paired exome analysis of Barrett's esophagus and adenocarcinoma
Stachler, M. D., Taylor-Weiner, A., Peng, S., McKenna, A., Agoston, A. T., Odze, R. D., Davison, J. M., Nason, K. S., Loda, M., Leshchiner, I., et al. (2015) · Nature Genetics · doi:10.1038/ng.3343 · Cited by 364
Self-citationDifferential DNA mismatch repair underlies mutation rate variation across the human genome
Supek, F., & Lehner, B. (2015) · Nature · doi:10.1038/nature14173 · Cited by 350
Stromal biology and therapy in pancreatic cancer: ready for clinical translation?
Neesse, A., Bauer, C. A., Öhlund, D., Lauth, M., Buchholz, M., Michl, P., Tuveson, D. A., & Gress, T. M. (2019) · Gut · doi:10.1136/gutjnl-2018-316451 · Cited by 353
Genome sequencing of normal cells reveals developmental lineages and mutational processes
Behjati, S., Huch, M., van Boxtel, R., Karthaus, W., Wedge, D. C., Tamuri, A. U., Martincorena, I., Petljak, M., Alexandrov, L. B., Gundem, G., et al. (2014) · Nature · doi:10.1038/nature13448 · Cited by 357
Spectrum of diverse genomic alterations define non–clear cell renal carcinoma subtypes
Durinck, S., Stawiski, E. W., Pavía-Jiménez, A., Modrusan, Z., Kapur, P., Jaiswal, B. S., Zhang, N., Toffessi-Tcheuyap, V., Nguyen, T. T., Pahuja, K. B., et al. (2015) · Nature Genetics · doi:10.1038/ng.3146 · Cited by 357
Pan-Cancer Landscape of Aberrant DNA Methylation across Human Tumors
Saghafinia, S., Mina, M., Riggi, N., Hanahan, D., & Ciriello, G. (2018) · Cell Reports · doi:10.1016/j.celrep.2018.09.082 · Cited by 357
Ling, S., Hu, Z., Yang, Z., Yang, F., Li, Y., Lin, P., Chen, K., Dong, L., Cao, L., Tao, Y., et al. (2015) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1519556112 · Cited by 352
Self-citationTargeted Therapy for Advanced Thyroid Cancer: Kinase Inhibitors and Beyond
Cabanillas, M. E., Ryder, M., & Jimenez, C. (2019) · Endocrine Reviews · doi:10.1210/er.2019-00007 · Cited by 335
A genomic and epigenomic atlas of prostate cancer in Asian populations
Li, J., Xu, C., Lee, H. J., Ren, S., Zi, X., Zhang, Z., Wang, H., Yu, Y., Yang, C., Gao, X., et al. (2020) · Nature · doi:10.1038/s41586-020-2135-x · Cited by 344
Cancer Evolution: Mathematical Models and Computational Inference
Beerenwinkel, N., Schwarz, R. F., Gerstung, M., & Markowetz, F. (2015) · Systematic Biology · doi:10.1093/sysbio/syu081 · Cited by 345
“More recent methods incorporate additional covariates, such as replication timing and gene expression data to refine estimates of the local mutation rate (Lawrence et al. 2013).”
MethodDadhania, V., Zhang, M., Zhang, L., Bondaruk, J., Majewski, T., Siefker-Radtke, A., Guo, C. C., Dinney, C., Cogdell, D. E., Zhang, S., et al. (2016) · EBioMedicine · doi:10.1016/j.ebiom.2016.08.036 · Cited by 345
Rotte, A., Jin, J. Y., & Lemaire, V. (2018) · Annals of Oncology · doi:10.1093/annonc/mdx686 · Cited by 344
Pangenomic Classification of Pituitary Neuroendocrine Tumors
Neou, M., Villa, C., Armignacco, R., Jouinot, A., Raffin-Sanson, M.-L., Septier, A., Letourneur, F., Diry, S., Diedisheim, M., Izac, B., et al. (2020) · Cancer Cell · doi:10.1016/j.ccell.2019.11.002 · Cited by 340
Pandey, G. K., Mitra, S., Subhash, S., Hertwig, F., Kanduri, M., Mishra, K., Fransson, S., Ganeshram, A., Mondal, T., Bandaru, S., et al. (2014) · Cancer Cell · doi:10.1016/j.ccell.2014.09.014 · Cited by 343
“3 algorithm (Lawrence et al., 2013) for all NBL sets, only the differentially expressed ALK and the nondifferentially expressed ZNF717 were found to be significantly mutated.”
BackgroundOnco-Multi-OMICS Approach: A New Frontier in Cancer Research
Chakraborty, S., Hosen, M. I., Ahmed, M., & Shekhar, H. U. (2018) · BioMed Research International · doi:10.1155/2018/9836256 · Cited by 335
“For example, in a large scale project known as “The Cancer Genome Atlas (TCGA)”, the scientists employed the NGS coupled with downstream bioinformatics analysis to discover somatic mutational landscape across thousands of tumor samples representing major cancer types under the assumption that these genome-wide mutatio…”
BackgroundHenderson, S., Chakravarthy, A., Su, X., Boshoff, C., & Fenton, T. R. (2014) · Cell Reports · doi:10.1016/j.celrep.2014.05.012 · Cited by 345
Implementing TMB measurement in clinical practice: considerations on assay requirements
Büttner, R., Longshore, J. W., López-Ríos, F., Merkelbach-Bruse, S., Normanno, N., Rouleau, E., & Penault-Llorca, F. (2019) · ESMO Open · doi:10.1136/esmoopen-2018-000442 · Cited by 345
The mutational landscapes of genetic and chemical models of Kras-driven lung cancer
Westcott, P. M. K., Halliwill, K. D., To, M. D., Rashid, M., Rust, A. G., Keane, T. M., Delrosario, R., Jen, K.-Y., Gurley, K. E., Kemp, C. J., et al. (2015) · Nature · doi:10.1038/nature13898 · Cited by 330
Worst, B. C., van Tilburg, C. M., Balasubramanian, G. P., Fiesel, P., Witt, R., Freitag, A., Boudalil, M., Previti, C., Wolf, S., Schmidt, S., et al. (2016) · European Journal of Cancer · doi:10.1016/j.ejca.2016.06.009 · Cited by 330
Molecular Characterization and Clinical Relevance of Metabolic Expression Subtypes in Human Cancers
Peng, X., Chen, Z., Farshidfar, F., Xu, X., Lorenzi, P. L., Wang, Y., Cheng, F., Tan, L., Mojumdar, K., Du, D., et al. (2018) · Cell Reports · doi:10.1016/j.celrep.2018.03.077 · Cited by 341
Self-citation
Metadata
- Authors
- Lawrence, M. S., Stojanov, P., Polak, P., Kryukov, G. V., Cibulskis, K., Sivachenko, A., Carter, S. L., Stewart, C., Mermel, C. H., Roberts, S. A., Kiezun, A., Hammerman, P. S., McKenna, A., Drier, Y., Zou, L., Ramos, A. H., Pugh, T. J., Stransky, N., Helman, E., Kim, J., Sougnez, C., Ambrogio, L., Nickerson, E., Shefler, E., Cortés, M. L., Auclair, D., Saksena, G., Voet, D., Noble, M., DiCara, D., Lin, P., Lichtenstein, L., Heiman, D. I., Fennell, T., Imielinski, M., Hernandez, B., Hodis, E., Baca, S., Dulak, A. M., Lohr, J., Landau, D.-A., Wu, C. J., Melendez-Zajgla, J., Hidalgo-Miranda, A., Koren, A., McCarroll, S. A., Mora, J., Lee, R. S., Crompton, B., Onofrio, R., Parkin, M., Winckler, W., Ardlie, K., Gabriel, S. B., Roberts, C. W. M., Biegel, J. A., Stegmaier, K., Bass, A. J., Garraway, L. A., Meyerson, M., Golub, T. R., Gordenin, D. A., Sunyaev, S., Lander, E. S., & Getz, G.
- Affiliations
- Broad Institute (US)
- National Institutes of Health (US)
- Harvard University (US)
- Hospital Sant Joan de Déu Barcelona (ES)
- Boston Children's Hospital (US)
- Children's Hospital of Philadelphia (US)
- Corresponding author
- Lander, Eric S.
- Getz, Gad
- ORCID
- Lawrence, Michael S.
- Polak, Paz
- Kryukov, Gregory V.
- Cibulskis, Kristian
- Sivachenko, Andrey
- Carter, Scott L.
- Stewart, Chip
- Mermel, Craig H.
- Roberts, Steven A.
- Hammerman, Peter S.
- McKenna, Aaron
- Drier, Yotam
- Zou, Lihua
- Pugh, Trevor J.
- Stransky, Nicolas
- Helman, Elena
- Kim, Jaegil
- Auclair, Daniel
- Saksena, Gordon
- Noble, Michael
- Lin, Pei
- Heiman, David I.
- Imielinski, Marcin
- Hernandez, Bryan
- Hodis, Eran
- Baca, Sylvan
- Dulak, Austin M.
- Lohr, Jens
- Landau, Dan-Avi
- Wu, Catherine J.
- Koren, Amnon
- McCarroll, Steven A.
- Mora, Jaume
- Crompton, Brian
- Winckler, Wendy
- Ardlie, Kristin
- Gabriel, Stacey B.
- Roberts, Charles W. M.
- Biegel, Jaclyn A.
- Stegmaier, Kimberly
- Bass, Adam J.
- Garraway, Levi A.
- Meyerson, Matthew
- Golub, Todd R.
- Gordenin, Dmitry A.
- Sunyaev, Shamil
- Lander, Eric S.
- Getz, Gad
- Venue
- Nature
- Published
- 2013-06-16
- Volume
- 499
- Issue
- 7457
- Pages
- 214-218
- ISSN
- 0028-0836 (ISSN-L)
- 1476-4687
- PMC
- PMC3919509
- OpenAlex
- W2009720434
- Cited by
- 5,461
- References
- 30
- Citations by year
- 2026: 147 · 2025: 230 · 2024: 288 · 2023: 361 · 2022: 468 · 2021: 580 · 2020: 582 · 2019: 507 · 2018: 537 · 2017: 529 · 2016: 485 · 2015: 396 · 2014: 280 · 2013: 64
- FWCI
- 143.48
- Type
- journal article
- Language
- en
- Open access
- green
- www.ncbi.nlm.nih.gov
- Licence
- www.springer.com/tdm (tdm)
- Locations
- Nature (publishedVersion)
- PubMed (publishedVersion)
- Europe PMC (PubMed Central) (acceptedVersion)
- PubMed Central (acceptedVersion)
- Digital Access to Scholarship at Harvard (DASH) (Harvard University) (submittedVersion, cc-by)
- RePEc: Research Papers in Economics (submittedVersion)
- DSpace@MIT (Massachusetts Institute of Technology) (submittedVersion, cc-by-nc-sa)
- Funders
- Howard Hughes Medical Institute
- National Institutes of Health
- National Human Genome Research Institute (U54HG003067)
- National Cancer Institute (U24CA143845, T32CA009216, T32CA009172)
- National Institute of General Medical Sciences (T32GM007753)
- National Institute of Environmental Health Sciences (Z01ES065073)
- Topics
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Cancer Research › Cancer Genomics and Diagnostics
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › Chromatin Remodeling and Cancer
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › Genomics and Phylogenetic Studies
- Keywords
- mutational heterogeneity, cancer genes, MutSigCV, driver mutations, mutation frequency, lung cancer, lung squamous cell carcinoma, DNA replication timing, transcriptional activity
- MeSH terms
- False Positive Reactions, Humans, Lung Neoplasms, Mutation, Neoplasms, Oncogenes, Reproducibility of Results, Gene Expression, Genome, Human, Artifacts, Neoplasms, Squamous Cell, Sample Size, Genetic Heterogeneity, DNA Replication Timing, Exome, Mutation Rate
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.